Relmada Therapeutics licenses Phase 2 Bladder Cancer candidate from Trigone

Relmada Therapeutics (RLMD) announced the completion of an exclusive licensing agreement with Trigone Pharma for NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel for the treatment of Non-Muscle Invasive Bladder Cancer. The efficacy and safety of the NDV-01 are being evaluated in a Phase 2 study. First data are expected to be reported at the American Urological Association meeting, being held April 26-29, 2025 in Las Vegas. “We are delighted to add NDV-01 to our pipeline as we believe it represents an exceptional value-creation opportunity for Relmada and our investors. The drug development expertise of our Team provides flexibility to be opportunistic and consider programs that have the potential to be high-value assets and that can demonstrate proof-of-concept in the near-term, regardless of therapeutic area. NDV-01 is an excellent fit with that profile,” said Sergio Traversa, CEO of Relmada Therapeutics.